Audentes Therapeutics (NASDAQ:BOLD) Given a $48.00 Price Target by HC Wainwright Analysts

HC Wainwright set a $48.00 price target on Audentes Therapeutics (NASDAQ:BOLD) in a research note released on Wednesday, May 8th, TipRanks reports. The firm currently has a buy rating on the biotechnology company’s stock.

Several other equities analysts also recently issued reports on BOLD. Zacks Investment Research raised shares of Audentes Therapeutics from a hold rating to a buy rating and set a $28.00 price target for the company in a report on Tuesday, January 8th. Guggenheim raised shares of Audentes Therapeutics from a neutral rating to a buy rating and set a $35.00 target price for the company in a research note on Friday, January 11th. William Blair reaffirmed a hold rating on shares of Audentes Therapeutics in a research note on Thursday, January 31st. Cowen reaffirmed a buy rating on shares of Audentes Therapeutics in a research note on Thursday, January 31st. Finally, Mizuho reaffirmed a buy rating and issued a $45.00 target price on shares of Audentes Therapeutics in a research note on Friday, February 1st. Two investment analysts have rated the stock with a sell rating, three have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus target price of $39.92.

Shares of Audentes Therapeutics stock opened at $35.12 on Wednesday. Audentes Therapeutics has a twelve month low of $17.95 and a twelve month high of $46.18. The stock has a market cap of $1.57 billion, a PE ratio of -10.33 and a beta of 1.85.

Audentes Therapeutics (NASDAQ:BOLD) last announced its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($1.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.23). During the same quarter in the previous year, the company earned ($0.74) EPS. Analysts anticipate that Audentes Therapeutics will post -4.43 earnings per share for the current year.

In related news, VP Suyash Prasad sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $36.98, for a total transaction of $369,800.00. Following the completion of the sale, the vice president now directly owns 28,236 shares of the company’s stock, valued at $1,044,167.28. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Louis G. Lange sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $36.00, for a total transaction of $720,000.00. Following the sale, the director now directly owns 306,099 shares of the company’s stock, valued at $11,019,564. The disclosure for this sale can be found here. Insiders own 5.30% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the stock. NumerixS Investment Technologies Inc boosted its holdings in shares of Audentes Therapeutics by 1,200.0% in the fourth quarter. NumerixS Investment Technologies Inc now owns 1,300 shares of the biotechnology company’s stock valued at $27,000 after buying an additional 1,200 shares during the period. Amundi Pioneer Asset Management Inc. acquired a new position in shares of Audentes Therapeutics in the fourth quarter valued at approximately $92,000. Great West Life Assurance Co. Can boosted its holdings in shares of Audentes Therapeutics by 96.0% in the fourth quarter. Great West Life Assurance Co. Can now owns 4,726 shares of the biotechnology company’s stock valued at $97,000 after buying an additional 2,315 shares during the period. BlueMountain Capital Management LLC acquired a new position in shares of Audentes Therapeutics in the first quarter valued at approximately $137,000. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its holdings in shares of Audentes Therapeutics by 46.1% in the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 6,280 shares of the biotechnology company’s stock valued at $138,000 after buying an additional 1,983 shares during the period. Hedge funds and other institutional investors own 98.71% of the company’s stock.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

Featured Story: Do investors pay a separate front-end load every time they buy additional shares?

Analyst Recommendations for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.